Part of: S&P 100 · Pharma & Biotech · Income & Dividends

Johnson & Johnson (JNJ)

AI-powered earnings call analysis for Johnson & Johnson. Get insights from quarterly earnings reports with our AI-generated podcast. Educational content only - not investment advice.

15 episodes 5 languages

Latest Episode

Q3 2026 Earnings

6:16 • 10/14/2026

Johnson & Johnson (JNJ) - Q3 2026

0:00

6:16

Speed:

Q3 2026 Earnings

6:49 • 2026/10/14

Johnson & Johnson (JNJ) - Q3 2026

0:00

6:49

Speed:

Q3 2026 Earnings

8:46 • 14/10/2026

Johnson & Johnson (JNJ) - Q3 2026

0:00

8:46

Speed:

Q3 2026 Earnings

8:49 • 14/10/2026

Johnson & Johnson (JNJ) - Q3 2026

0:00

8:49

Speed:

Q3 2026 Earnings

6:13 • 14.10.2026

Johnson & Johnson (JNJ) - Q3 2026

0:00

6:13

Speed:

All Episodes

EN - English (3) CN - 中文 (3) FR - Français (3) ES - Español (3) DE - Deutsch (3)

Q3 2026 Earnings

6:16

Johnson & Johnson reported Q3 revenue of $25.4B with 6% operational growth and raised full-year guidance, driven by Innovative Medicine strength while managing MedTech headwinds outside the U.S.

Q2 2026 Earnings

6:21

Johnson & Johnson's Q2 2026 sales grew 5.6% to $25.3B, beating guidance and raising full-year outlook to $100.6B, driven by strong Innovative Medicine and new product momentum.